Unknown

Dataset Information

0

Synergistic actions of FGF2 and bone marrow transplantation mitigate radiation-induced intestinal injury.


ABSTRACT: Unwanted radiological or nuclear exposure remains a public health risk for which effective therapeutic countermeasures are lacking. Here, we evaluated the efficacy of fibroblast growth factor-2 (FGF2) in treating radiation-induced gastrointestinal syndrome (RIGS) incurred by lethal whole-body irradiation (WBI) when administered in conjunction with bone marrow transplantation (BMT). In vitro experiments indicated FGF2 treatment increased proliferation, reduced apoptosis, and upregulated AKT-GSK3?/?-catenin signaling in irradiated IEC-6 cells. We next established and analyzed mice cohorts consisting of sham irradiation (Group Sh); 12?Gy WBI (Group A); WBI with BMT (Group B); WBI with FGF2 treatment (Group F); and WBI with BMT and FGF2 treatment (Group BF). At 2 weeks post-irradiation, Group BF showed a dramatic increase in survival over all other groups. Intestinal epithelium of Group BF, but not Group B or F, showed augmented proliferation, decreased apoptosis, and preserved crypt numbers and morphology. Furthermore, Group BF maintained intestinal barrier function with minimal inflammatory disturbances in a manner comparable to Group Sh. In accordance, transcriptomic analyses showed significant upregulation of intestinal barrier and stem cell markers in Group BF relative to Groups A and B. Taken together, parenteral FGF2 synergizes with BMT to confer potent mitigation against RIGS.

SUBMITTER: Kim BH 

PROVIDER: S-EPMC5841425 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Synergistic actions of FGF2 and bone marrow transplantation mitigate radiation-induced intestinal injury.

Kim Byoung Hyuck BH   Jung Hee-Won HW   Seo Seok Hyun SH   Shin Hyemi H   Kwon Jeanny J   Suh Jae Myoung JM  

Cell death & disease 20180307 3


Unwanted radiological or nuclear exposure remains a public health risk for which effective therapeutic countermeasures are lacking. Here, we evaluated the efficacy of fibroblast growth factor-2 (FGF2) in treating radiation-induced gastrointestinal syndrome (RIGS) incurred by lethal whole-body irradiation (WBI) when administered in conjunction with bone marrow transplantation (BMT). In vitro experiments indicated FGF2 treatment increased proliferation, reduced apoptosis, and upregulated AKT-GSK3β  ...[more]

Similar Datasets

| S-EPMC4096810 | biostudies-literature
| S-EPMC7835034 | biostudies-literature
| S-EPMC3348096 | biostudies-literature
| S-EPMC5749546 | biostudies-other
| S-EPMC3174150 | biostudies-literature
| S-EPMC6237572 | biostudies-literature
| 2004880 | ecrin-mdr-crc
| S-EPMC3580267 | biostudies-literature
| S-EPMC8235137 | biostudies-literature
| S-EPMC3254014 | biostudies-other